MoonLake menjadwalkan pertemuan Type B FDA untuk paket BLA sonelokimab HS

Kutipan sumber

EX-99.1 2 moonlake-pressreleasexq320.htm EX-99.1 Document MoonLake Immunotherapeutics Melaporkan Hasil Keuangan Kuartal Ketiga 2025 dan Mengumumkan Data Baru dari Uji Klinis Nanobody® Sonelokimab-nya • Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027 • Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefit • Reported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim a

SEC 8-K

Selengkapnya tentang aset ini

Penentu

22 Jun 2026

11.00

MLTXMoonLake

MoonLake melaporkan data VELA Fase 3 Minggu 52 untuk sonelokimab pada HS

Hasil toplineSEC 8-KBuka catatan10 pembaruan

Material

11 Mei 2026

11.09

MLTXMoonLake

MoonLake: FDA selaras pada rencana pra-BLA untuk sonelokimab dalam HS

LainnyaSEC 8-KBuka catatan